TO OZEMPIC OR NOT TO OZEMPIC?

Dr Jack Mosley, son of the late Dr Michael Mosley, weighs in

- 

Touted as one of the greatest medical breakthroughs of the decade, GLP-1 weight-loss drugs (such as Ozempic, Wegovy, Mounjaro and Zepbound) have not only revolutionised the way we tackle type 2 diabetes, they've also moved into the mainstream.

As WeightWatchers files for bankruptcy, the semaglutides market is expected to be worth £82.3bn by 2035, with the jabs becoming the most coveted status-symbol peddled by the rapidly shrinking bodies we see on red carpets and in our social feeds.

But in the midst of what has become a tensionfilled landscape, beset by growing ethical concerns and regulation issues, Dr Jack Mosley, GP registrar and expert in GLP-1 drugs, has stepped in as a beacon of common sense with his new book Food Noise: How Weight-Loss Medications and Smart Nutrition Can Silence Your Cravings.

Having dedicated the book to his late father Dr Michael Mosley, a much-loved fixture on our screens and airwaves whose work has had a lasting impact on the nation's health (Michael pioneered the popular 5:2 diet), Jack is keen to continue in his own way the Mosley mission to help us lead healthier lives.

"My father taught me that health isn't just about numbers on a scale. My book is dedicated to him, and to everyone looking for a better, quieter relationship with food," he says. Here, we ask him the (fat) burning questions on everyone's lips. An expert in GLP-1 weightloss drugs, Jack is keen to ensure that potential users of these medications are fully informed about the pros and cons

Jack, why is “food noise” louder than ever?

“In our modern Western food environment, we are exposed to more ‘food noise’ — the inner voice that urges us to eat — than at any time in our history as a species.